Practical Selection for Doublet versus Triplet Therapy

How to cite: Petrylak DP. Practical Selection for Doublet versus Triplet Therapy. Grand Rounds in Urology. February 2026. Accessed Oct 2026. https://grandroundsinurology.com/practical-selection-for-doublet-versus-triplet-therapy/

Summary

Daniel P. Petrylak, MD, Professor of Medicine, Yale University Cancer Center, New Haven, Connecticut, reviews the evolving treatment landscape for metastatic hormone-sensitive prostate cancer and emphasizes that intensification beyond androgen deprivation therapy (ADT) is now the standard of care. Treatment options include doublet therapy with androgen receptor-directed agents plus ADT and triplet therapy incorporating docetaxel with androgen receptor-directed therapy and ADT. 

Dr. Petrylak highlights that randomized trials consistently demonstrate a survival benefit with treatment intensification. Doublet therapy reduces the risk of death by approximately 30% to 50% percent compared with ADT alone, while triplet therapy provides additional benefit in selected populations, although cross-trial comparisons are limited by differences in study design and patient populations.

He emphasizes the importance of clinical stratification when selecting therapy. High-volume disease, defined by visceral metastases or multiple bone lesions, and de novo metastatic presentation are associated with worse prognosis and may favor more aggressive approaches, including triplet therapy. In contrast, patients with low-volume or metachronous disease may achieve prolonged survival with doublet therapy.

Treatment selection is also guided by patient-specific factors, including performance status, comorbidities, and treatment tolerability. Dr. Petrylak reviews key toxicity profiles, noting cardiovascular and metabolic effects associated with abiraterone, fatigue and central nervous system effects with enzalutamide, and distinct tolerability considerations with other agents.

Emerging biomarkers may further refine treatment decisions. The Decipher genomic classifier may help identify patients who benefit from chemotherapy, while SPOP mutations are associated with enhanced response to androgen receptor-directed therapy and may predict resistance to docetaxel. However, these biomarkers remain exploratory and require prospective validation.

Dr. Petrylak emphasizes that while treatment intensification is essential, optimal selection between doublet and triplet therapy requires an individualized assessment that incorporates disease burden, patient characteristics, and evolving biomarker data.

The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 36 featured lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.

The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts.